Literature DB >> 15266207

Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial.

J Scott Roberts1, Melissa Barber, Tamsen M Brown, L Adrienne Cupples, Lindsay A Farrer, Susan A LaRusse, Stephen G Post, Kimberly A Quaid, Lisa D Ravdin, Norman R Relkin, A Dessa Sadovnick, Peter J Whitehouse, John L Woodard, Robert C Green.   

Abstract

PURPOSE: Alzheimer's disease, for which one form of the apolipoprotein E (APOE) genotype is a risk factor, provides a paradigm in which to examine response to susceptibility testing for common, complex diseases. This study's main purposes were to estimate interest in such testing and to examine demographic predictors of study participation.
METHODS: In this 3-site, randomized clinical trial (RCT), the intervention was a risk assessment program wherein genetic counselors educated adult children of AD patients about lifetime risk of disease based on their gender, family history, and APOE genotype. Two groups of participants were followed from initial contact to RCT enrollment: those who were systematically contacted through research registries, and those who were self-referred.
RESULTS: Of 196 systematically contacted participants, 47, or 24%, progressed from initial contact to RCT enrollment. These participants were more likely to be below age 60 (adjusted OR = 3.83, P < 0.01) and college educated (adjusted OR = 3.48, P < 0.01). Of 179 self-referred participants, 115, or 64%, progressed from initial contact to RCT enrollment. Most self-referred participants had a college education and were female (79%).
CONCLUSIONS: In the first RCT to examine genetic susceptibility testing for AD, uptake rates were sufficiently high to merit concern that future test demand may strain available education and counseling resources. Findings suggest that susceptibility testing for AD may be of particular interest to women, college educated persons, and persons below age 60.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266207     DOI: 10.1097/01.gim.0000132688.55591.77

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  37 in total

Review 1.  Communicating genetic risk information for common disorders in the era of genomic medicine.

Authors:  Denise M Lautenbach; Kurt D Christensen; Jeffrey A Sparks; Robert C Green
Journal:  Annu Rev Genomics Hum Genet       Date:  2013       Impact factor: 8.929

2.  Community engagement about genetic variation research.

Authors:  Sharon F Terry; Kurt D Christensen; Susan Metosky; Gayle Rudofsky; Kathleen P Deignan; Hulda Martinez; Penelope Johnson-Moore; Toby Citrin
Journal:  Popul Health Manag       Date:  2011-08-04       Impact factor: 2.459

3.  Informed Choice in Direct-to-Consumer Genetic Testing for Alzheimer and Other Diseases: Lessons from Two Cases.

Authors:  Donna A Messner
Journal:  New Genet Soc       Date:  2011

4.  Public beliefs and knowledge about risk and protective factors for Alzheimer's disease.

Authors:  J Scott Roberts; Sara J McLaughlin; Cathleen M Connell
Journal:  Alzheimers Dement       Date:  2014-03-14       Impact factor: 21.566

Review 5.  Predictors of genetic testing decisions: a systematic review and critique of the literature.

Authors:  Kate Sweeny; Arezou Ghane; Angela M Legg; Ho Phi Huynh; Sara E Andrews
Journal:  J Genet Couns       Date:  2014-04-11       Impact factor: 2.537

6.  A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Authors:  Robert C Green; Kurt D Christensen; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Charmaine D M Royal; Thomas O Obisesan; Robert Cook-Deegan; Erin Linnenbringer; Melissa Barber Butson; Grace-Ann Fasaye; Elana Levinson; J Scott Roberts
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

7.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

8.  Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.

Authors:  Cathleen D Zick; Charles J Mathews; J Scott Roberts; Robert Cook-Deegan; Robert J Pokorski; Robert C Green
Journal:  Health Aff (Millwood)       Date:  2005 Mar-Apr       Impact factor: 6.301

9.  Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates.

Authors:  Thomas R Fanshawe; A Toby Prevost; J Scott Roberts; Robert C Green; David Armstrong; Theresa M Marteau
Journal:  Genet Test       Date:  2008-09

10.  Disclosure of APOE genotype for risk of Alzheimer's disease.

Authors:  Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.